Collagenase 2/matrix metalloproteinase 8 in critically ill patients with secondary peritonitis

Shock

Volumn 27, Issue 2, 2007, Pages 145-150

  Hästbacka, Johanna ^a   Hynninen, Marja ^a   Kolho, Elina ^a   Pettilä, Ville ^a   Tervahartiala, Taina ^a   Sorsa, Timo ^a   Lauhio, Anneli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Collagenase 2; Critical illness; Infection; Matrix metalloproteinase; Matrix metalloproteinase 8; Peritoneal fluid; Peritonitis

Indexed keywords

COLLAGEN TYPE 1; COLLAGENASE 3; INTERSTITIAL COLLAGENASE; ISOENZYME; NEUTROPHIL COLLAGENASE;

ADULT; AGED; ARTICLE; CATALYSIS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CRITICALLY ILL PATIENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LOCALIZATION; FEMALE; FLUOROMETRY; HUMAN; MALE; MEASUREMENT; PERITONEAL FLUID; PERITONITIS; SERUM; STATISTICAL SIGNIFICANCE; URINE; WESTERN BLOTTING;

ADULT; AGED; ASCITIC FLUID; CRITICAL ILLNESS; FEMALE; HUMANS; ISOENZYMES; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; PERITONITIS;

EID: 33846228302     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000239771.10528.d3     Document Type: Article

References (33)

1. Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 31:2228-2237, 2003.
2. Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer RG: Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 7:117-121, 2001.
3. Emmanuel K, Weighardt H, Bartels H, Siewert J-R, Holzmann B: Current and future concepts of abdominal sepsis. World J Surg 29:3-9, 2005.
4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516, 2001.
5. Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi C: Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem 265:11421-11424, 1990.
6. Owen CA, Campbell EJ: The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 65:137-150, 1999.
7. Elkington PTG, O'Kane CM, Friedland JS: The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 142:12-20, 2005.
8. Fukudome K, Fujimoto S, Sato Y, Hisanga S, Eto T: Peritonitis increases MMP-9 activity in peritoneal effluent from CAPD patients. Nephron 87:35-41, 2001.
9. Overall CM, Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657-672, 2002.
10. Billing A, Frohlich D, Schildberg FW: Prediction of outcome using the Mannheim peritonitis index in 2003 patients. Peritonitis Study Group. Br J Surg 81:209-213, 1994.
11. Bergmann U, Michaelis J, Oberhoff R, Knäuper V, Beckmann R, Tschesche H: Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem 27:351-359, 1989.
12. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, van Hinsberg VWM, Helaakoski T, Kainulainen T, Rönkä H, et al.: Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-α and doxycycline. J Biol Chem 272:31504-31509, 1997.
13. Hemmilä I, Dakubu S, Mukkala VM, Siitari H, Lövgren T: Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 137:335-343, 1984.
14. Lauhio A, Salo T, Ding Y, Konttinen YT, Nordström D, Tschesche H, Lähdevirta J, Golub L, Sorsa T: In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol 98:21-28, 1994.
15. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 40:1391-1399, 1997.
16. Marshall BC, Santana A, Xu QP, Petersen MJ, Campbell EJ, Hoidal JR, Welgus HG: Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells: cellular differentiation influences expression. J Clin Invest 91:1792-1799, 1993.
17. de Hingh IHJT, Siemonsma MA, de Man BM, Lomme RMLM, Hendriks T: The matrix metalloproteinase inhibitor BB-94 improves the strength of intestinal anastomoses in the rat. Int J Colorectal Dis 17:348-354, 2002.
18. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD: Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 72:7791-7803, 2004.
19. Holzheimer RG, Schein M, Wittman DH: Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch Surg 130:1314-1320, 1995.
20. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344-353, 2006.
21. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002.
22. Volman TJH, Goris RJA, Lomme RMLM, DeGroot J, Verhofstad AAJ, Hendriks T: Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome. J Pathol 203:968-975, 2004.
23. Maitra SR, Shapiro MJ, Bhaduri S, El-Maghrabi MR: Effect of chemically modified tetracycline on transforming growth factor-β1 and caspase-3 activation in liver of septic rats. Crit Care Med 33:1577-1581, 2005.
24. Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J: Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 167:593-598, 2003.
25. Tashiro K, Koyanagi I, Ohara I, Ito T, Saitoh A, Horikoshi S, Tomino Y: Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 18:206-210, 2004.
26. Chromek M, Tullus K, Hertting O, Jaremko G, Khalil A, Li YH, Brauner A: Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res 53:698-705, 2003.
27. Speidl WS, Toller WG, Kaun C, Weiss TW, Pfaffenberger S, Kastl SP, Furnkranz A, Maurer G, Huber K, Metzler H, et al.: Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for perioperative plaque instability. FASEB J 18:603-605, 2004.
28. Aljada A, Ghanim H, Mohanty P, Hofmeyer D, Tripathy D, Dandona P: Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). J Clin Endocrinol Metab 86:5988-5991, 2001.
29. Muhs BE, Patel S, Yee H, Marcus S, Shamamiam P: Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res 109:110-117, 2003.
30. Steinberg J, Halter J, Schiller HJ, Dasilva M, Landas S, Gatto LA, Maisi P, Sorsa T, Rajamäki M, Lee H-M, et al.: Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 111:185-195, 2003.
31. Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N: Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 20:280-285, 2003.
32. Hu J, Van den Steen PE, Dillen C, Opdenakker G: Targeting neutrophil collagenase/ matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem Pharmacol 70:535-544, 2005.
33. Siemonsma MA, de Hingh IHJT, de Man BM, Lomme RMLM, Verhofstad AAJ, Hendriks T: Doxycycline improves wound strength after intestinal anastomosis in the rat. Surgery 133:268-276, 2003.